Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Eltanexor in High-Risk Myelodysplastic Syndrome
2021-003810-38Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltanexor in myelodysplastic syndrome (MDS), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Overall response rate. Started Nov 2021; status: completed.
02
Drugs
eltanexor
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2021-003810-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003810-38.